IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.924
EU - Europa 5.575
AS - Asia 3.383
SA - Sud America 261
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 4
Totale 16.188
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.902
SG - Singapore 1.261
CN - Cina 1.185
IE - Irlanda 1.016
UA - Ucraina 903
IT - Italia 767
SE - Svezia 761
FR - Francia 694
TR - Turchia 617
GB - Regno Unito 556
DE - Germania 387
BR - Brasile 233
IN - India 170
FI - Finlandia 151
RU - Federazione Russa 141
VN - Vietnam 70
AT - Austria 50
BE - Belgio 47
HK - Hong Kong 30
CZ - Repubblica Ceca 29
EU - Europa 17
CA - Canada 16
NL - Olanda 13
PL - Polonia 10
RO - Romania 10
AR - Argentina 8
EC - Ecuador 6
EG - Egitto 6
IL - Israele 6
MA - Marocco 6
AL - Albania 5
ID - Indonesia 5
UZ - Uzbekistan 5
AU - Australia 4
CH - Svizzera 4
DK - Danimarca 4
ES - Italia 4
GR - Grecia 4
LT - Lituania 4
PK - Pakistan 4
BO - Bolivia 3
CL - Cile 3
HR - Croazia 3
IQ - Iraq 3
JP - Giappone 3
KG - Kirghizistan 3
PY - Paraguay 3
TW - Taiwan 3
VE - Venezuela 3
AZ - Azerbaigian 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
IR - Iran 2
KE - Kenya 2
MX - Messico 2
NP - Nepal 2
PH - Filippine 2
PT - Portogallo 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BD - Bangladesh 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CO - Colombia 1
EE - Estonia 1
HU - Ungheria 1
JO - Giordania 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 16.188
Salva come PNG Salva come JPEG
Città #
Chandler 1.478
Jacksonville 1.167
Dublin 1.007
Singapore 850
Princeton 466
Southend 414
Izmir 376
Nanjing 342
Ashburn 271
Wilmington 224
Beijing 210
Dearborn 189
The Dalles 188
Ann Arbor 177
Cambridge 174
Altamura 167
Santa Clara 149
Boardman 148
Chieti 138
Nanchang 125
Woodbridge 93
Houston 80
Los Angeles 80
New York 77
Dong Ket 68
Shenyang 63
Hebei 60
Kunming 54
Tianjin 51
Brussels 47
Munich 46
Washington 43
Vienna 41
Jiaxing 40
Norwalk 37
Nuremberg 29
Pescara 29
Hong Kong 28
Rome 28
Helsinki 26
Changsha 23
Brno 22
Falls Church 22
Hangzhou 20
Milan 20
Seattle 20
São Paulo 20
Kocaeli 19
San Mateo 17
Lanzhou 16
Auburn Hills 14
Tappahannock 14
Changchun 13
Guangzhou 13
Düsseldorf 12
Grevenbroich 12
Shanghai 12
Augusta 11
Chicago 11
London 11
Ningbo 11
Edinburgh 10
Frontone 10
Jinan 9
Leawood 9
Rio de Janeiro 9
Zhengzhou 9
Belo Horizonte 8
Fairfield 8
Frankfurt am Main 8
Giaveno 8
Moscow 8
Mumbai 8
Aprilia 7
Hefei 7
Cairo 6
Collecorvino 6
Giulianova 6
Menlo Park 6
Orange 6
Romola 6
Toronto 6
Bristol 5
Campinas 5
Franca 5
Monmouth Junction 5
Ottawa 5
Pune 5
Redwood City 5
Tashkent 5
Amsterdam 4
Anzio 4
Denver 4
Haikou 4
Nanning 4
Napoli 4
Olomouc 4
Paris 4
Quito 4
Shaoxing 4
Totale 9.853
Salva come PNG Salva come JPEG
Nome #
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 147
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 139
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 125
A multidisciplinary group for prostate cancer management: A single institution experience 123
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 115
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 115
New Targets for Therapy in Pancreatic Cancer 114
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 114
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 109
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 108
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 106
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 106
90K (Mac-2 BP) in human milk 104
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 104
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 103
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 103
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 103
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 102
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 101
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 101
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 101
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 101
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 100
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 100
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 99
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 97
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 97
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 96
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 96
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 96
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 95
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 95
Surgical treatment of adrenal metastases from non small cell lung cancer 94
DNA ploidy and S-phase fraction in pulmonary carcinoids. 94
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 94
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 94
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 94
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 94
Tyrosine kinase inhibitors 93
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 92
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 92
Chemotherapy preoperative for the management of breast cancer locally advanced 92
Principali effetti collaterali delle terapie mediche 92
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 92
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 92
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 91
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 90
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 90
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 89
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 88
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 88
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 88
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 87
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 87
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 87
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 86
Unknown primary tumors 86
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 86
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 86
Interleukin-30 Promotes Breast Cancer Growth and Progression 85
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 85
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 85
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 85
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 84
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 83
Tumor-derived microvesicles: The metastasomes. 83
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 83
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 83
Prognostic value of 90K protein in HIV infection 82
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 82
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 82
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 82
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 82
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 82
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 81
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 81
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 80
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 80
A Flow cytometric study of early gastric cancer 80
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 80
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies 80
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 80
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 80
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 80
Prognostic value of a novel circulating serum 90K antigen in breast cancer 79
Immunological effects of alternative weekly interferon–alpha–2b and low dose interleukin–2 in patients with cancer 79
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 79
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 79
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 79
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 78
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 77
Circadian timing of chemotherapeutic agents:a phase II study of 5-fluoro-2-deoxyuridine in gastrointestinal cancer and renal cell carcinoma 77
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 77
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 77
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 77
Neoadjuvant chemotherapy with cisplatin, epirubicin and VP-16 for stage IIIA-IIIB non-small-cell lung cancer: a pilot study. 77
Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis 77
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 76
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 76
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 76
Totale 9.143
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.585
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.585
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020347 0 0 0 0 0 0 0 0 0 0 322 25
2020/20211.456 228 22 278 12 90 287 34 43 97 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20252.802 202 692 532 115 86 173 137 218 355 188 104 0
Totale 17.033